Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)

BACKGROUND: Immune checkpoint inhibitors (ICIs) have emerged as promising therapeutic agents in non-small cell lung cancer (NSCLC). However, the duration for which ICIs should be continued remains a clinical problem. METHODS: We examined the efficacy of anti-PD-1/PD-L1 inhibitors after the discontin...

Descripción completa

Detalles Bibliográficos
Autores principales: Tachihara, Motoko, Negoro, Shunichi, Inoue, Takako, Tamiya, Motohiro, Akazawa, Yuki, Uenami, Takeshi, Urata, Yoshiko, Hattori, Yoshihiro, Hata, Akito, Katakami, Nobuyuki, Yokota, Soichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171229/
https://www.ncbi.nlm.nih.gov/pubmed/30285770
http://dx.doi.org/10.1186/s12885-018-4819-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171229/
https://www.ncbi.nlm.nih.gov/pubmed/30285770
http://dx.doi.org/10.1186/s12885-018-4819-2

Ejemplares similares